DIN 00839191 — SANDOSTATIN 50 MCG
SANDOSTATIN is a solution of Octreotide marketed by NOVARTIS PHARMACEUTICALS CANADA INC. The full Octreotide monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 00839191
- Brand name
- SANDOSTATIN
- Active ingredient
- Octreotide
- Strength
- 50 MCG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS; SUBCUTANEOUS
- Manufacturer
- NOVARTIS PHARMACEUTICALS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Somatostatin analogue
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.
Other Octreotide products
| DIN | Brand | Strength | Form | Manufacturer | Status |
|---|---|---|---|---|---|
| 02248640 | OCTREOTIDE ACETATE OMEGA | 100 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED |
| 02248642 | OCTREOTIDE ACETATE OMEGA | 200 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED |
| 02248639 | OCTREOTIDE ACETATE OMEGA | 50 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED |
| 02248641 | OCTREOTIDE ACETATE OMEGA | 500 MCG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED |
| 02567776 | OCTREOTIDE DEPOT | 10 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | STERIMAX INC | MARKETED |
| 02567784 | OCTREOTIDE DEPOT | 20 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | STERIMAX INC | MARKETED |
| 02567792 | OCTREOTIDE DEPOT | 30 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | STERIMAX INC | MARKETED |
| 02560240 | OCTREOTIDE INJECTION | 100 MCG | SOLUTION | STERIMAX INC | MARKETED |
| 02560283 | OCTREOTIDE INJECTION | 200 MCG | SOLUTION | STERIMAX INC | MARKETED |
| 02560291 | OCTREOTIDE INJECTION | 500 MCG | SOLUTION | STERIMAX INC | MARKETED |
| 02239323 | SANDOSTATIN LAR | 10 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02239324 | SANDOSTATIN LAR | 20 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |
| 02239325 | SANDOSTATIN LAR | 30 MG | POWDER FOR SUSPENSION (SUSTAINED-RELEASE | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED |